3D Systems Plunges 35.48% on $42.5M Offering, Akebia Drops 34.28% on Revenue Miss, Precision BioScience Surges 22.76%

Mumbai, 5 November 2026: The US stock market saw mixed trading as investors reacted to quarterly earnings, revised financial guidance, corporate acquisitions and major financing announcements. While some companies gained despite earnings beats or strategic developments, others faced sharp declines following revenue misses, weaker outlooks and equity offerings.

Notable movers included Advanced Drainage Systems, Oscar Health, Palantir, Agility Robotics and 3D Systems, alongside several companies announcing significant business transactions and capital-raising plans.

Advanced Drainage Systems Shares Fall 12.84% After Revenue Miss and Guidance Cut

Advanced Drainage Systems reported fiscal second-quarter 2027 adjusted earnings per share of $1.88, exceeding the analyst consensus estimate of $1.79 by 5.2%. However, net sales of $889.4 million increased 4.6% year over year but missed the $930 million consensus estimate by 4.4%. The sales growth was entirely attributable to the National Diversified Sales (NDS) acquisition, which contributed $77.3 million to Stormwater revenue. Excluding the acquisition, organic Stormwater sales declined 5.3%, while Wastewater sales fell 1.3%.

The company reduced its fiscal 2027 net sales guidance to $3.30 billion-$3.40 billion, compared with its previous range of $3.35 billion-$3.55 billion. Management cited higher interest rates and geopolitical uncertainty as demand headwinds. It also indicated that revenue pulled forward into the first quarter was higher than previously anticipated, at an estimated $40 million-$50 million. Meanwhile, the adjusted EBITDA outlook was narrowed to $1.00 billion-$1.03 billion from $1.00 billion-$1.05 billion, while the targeted adjusted EBITDA margin remained above 30%.

Advanced Drainage Systems shares were down 12.84% at $125.58 as of 11:39:39 a.m. EST on November 5, 2026, compared with the previous close of $144.07. The stock opened at $122.70 and recorded a high of $130.73 and a low of $124.54 during the session.

The company also raised its quarterly dividend by 11% to $0.20 per share and disclosed a proposed $530 million acquisition of StormTrap, expected to close in the fourth quarter of calendar 2026.

Oscar Health Shares Fall 1.35% Despite Q3 Earnings Beat and 72.1% Revenue Growth

Oscar Health reported third-quarter 2026 revenue of $5.14 billion, an increase of 72.1% year over year and 8.4% above analysts’ consensus estimate of $4.74 billion. GAAP earnings came in at $0.49 per share, significantly exceeding analysts’ expectations of a loss of $0.17 per share. This compared with a loss of $0.53 per share in the same quarter last year.

Adjusted EBITDA increased 304% year over year to $206.9 million, representing a 4% margin. The operating margin improved to 3.5% from negative 4.3% in the year-ago quarter. However, free cash flow remained negative at $1.21 billion, compared with negative $973.7 million a year earlier.

For full-year 2026, Oscar Health projected revenue of approximately $19.15 billion at the midpoint, 2.2% above analysts’ consensus estimates. CEO Mark Bertolini said the company was raising its earnings-from-operations outlook for the third time, citing disciplined pricing, consumer-focused products and technology-driven operations.

Oscar Health shares were trading at $34.72, down $0.47 or 1.35%, as of 12:13:07 p.m. EST on November 5, 2026, compared with the previous close of $35.19. The stock opened at $34.31 and recorded a high of $38.50 and a low of $34.10 during the session.

Also Read: What Is the New York Stock Exchange (NYSE)?

Kimberly-Clark Shares Rise 0.68% Despite Q3 Sales Decline and Margin Pressure

Kimberly-Clark Corporation reported mixed third-quarter 2026 results, with adjusted earnings exceeding analysts’ expectations while revenue fell short. Adjusted earnings from continuing operations increased 17.2% year over year to $1.70 per share, beating the Zacks Consensus Estimate of $1.66. However, net sales declined 0.4% to $4.134 billion, missing the consensus estimate of $4.147 billion. The earnings improvement was primarily supported by lower net interest expenses and a reduced adjusted effective tax rate.

Organic sales declined 1.3%, reflecting pricing pressures, weaker performance in China and retail inventory movements in North America. The China social media disruption created an approximately 270-basis-point headwind to organic sales. Adjusted gross margin contracted 130 basis points to 35.5%, while adjusted operating profit decreased 0.9% to $677 million from $683 million a year earlier.

Performance varied across business segments. North America’s net sales increased 0.9% to $2.738 billion, supported by supply-agreement transactions and organic sales growth. Its operating profit rose 2.7% to $657 million. In contrast, International Personal Care sales declined 2.8% to $1.396 billion, while operating profit fell 32.7% to $144 million, primarily reflecting weakness in China and higher input costs.

Kimberly-Clark shares were trading at $109.62, up 0.68%, as of 12:36 p.m. EST on November 5, 2026. The stock opened at $108.30 and recorded a high of $112.85 and a low of $108.30 during the session.

Akebia Therapeutics Shares Plunge 34.28% After Q3 Revenue Miss and Wider Loss

Akebia Therapeutics reported a third-quarter 2026 adjusted loss of $0.04 per share, compared with the Zacks Consensus Estimate of a loss of $0.03 per share and break-even earnings in the year-ago quarter. The loss represented a negative earnings surprise of 33.33%. Revenue for the quarter ended September 2026 declined to $36.9 million from $58.77 million a year earlier, missing the Zacks Consensus Estimate by 21.27%.

The decline in revenue was primarily driven by lower sales of Auryxia, whose net product revenue fell to $20 million from $42.5 million. Meanwhile, Vafseo net product revenue increased 3% year over year to $14.8 million, despite a roughly 140% increase in patients receiving the treatment to approximately 11,500. A major customer reduced inventory purchases, limiting reported revenue growth. Akebia estimated underlying Vafseo demand at $19 million-$20 million during the quarter.

The company reported a net loss of $14.4 million, compared with net income of $500,000 in the corresponding quarter last year. Cash and cash equivalents stood at $159.3 million at the end of September. Management expects its existing cash, anticipated revenue and planned loan refinancing to support operations for at least two years.

Akebia Therapeutics shares were trading at $0.4568, down $0.2379 or 34.28%, as of 12:46:17 p.m. EST on November 5, 2026, compared with the previous close of $0.6947. The stock opened at $0.5100 and recorded a session high of $0.5475 and a low of $0.4500.

Aspen Aerogels Shares Rise 0.73% After Third-Quarter Earnings and Revenue Beat Estimates

Aspen Aerogels reported adjusted third-quarter 2026 earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. The company had reported an adjusted loss of $0.06 per share in the year-ago quarter. The latest results represented an earnings surprise of 222.22%.

Revenue for the quarter ended September 2026 reached $85.18 million, exceeding the Zacks Consensus Estimate by 17.85%. This compared with revenue of $73.02 million in the corresponding quarter last year. Aspen Aerogels has surpassed consensus revenue estimates in three of the past four quarters, although it has beaten earnings estimates only once during that period.

Ahead of the earnings release, estimate revisions for the company were mixed, resulting in a Zacks Rank #3 (Hold). The current consensus estimate for the coming quarter stands at a loss of $0.10 per share on revenue of $65.23 million. For the current fiscal year, analysts expect a loss of $0.76 per share and revenue of $225.2 million.

Aspen Aerogels shares were trading at $4.8350, up $0.0350, or 0.73%, as of 11:36:31 a.m. EST on November 5, 2026. The stock had closed at $4.8000 in the previous session and opened at $4.9200. It recorded a high of $5.0300 and a low of $4.5300 during the session.

The shares have gained approximately 69.6% since the beginning of 2026, compared with a 12.3% advance in the S&P 500.

First Advantage Shares Rise 3.16% After $125 Million Data Diver Acquisition

First Advantage Corporation (NASDAQ: FA) announced the acquisition of Data Diver Technologies, LLC for approximately $125 million on November 5, 2026. The transaction is aimed at expanding First Advantage’s automated criminal and court records coverage across US jurisdictions and strengthening its background screening capabilities.

Data Diver Technologies operates an artificial intelligence (AI)- and automation-powered data platform that collects, aggregates, retains and delivers criminal and court records for background screening. The company has developed its proprietary platform over two decades and previously served as a third-party data provider to First Advantage.

The acquisition also includes a small employment background screening business catering to small and medium-sized businesses, which First Advantage plans to integrate into its existing operations. Data Diver Technologies’ management team will remain with First Advantage following the transaction.

First Advantage CEO Scott Staples said the company had worked with Data Diver Technologies for several years as a key third-party data provider. The company expects the acquisition to enhance fulfilment workflows and support product innovation.

First Advantage maintains more than one billion records in its proprietary databases, conducts over 200 million background screens annually across more than 200 countries and territories, and serves over 80,000 customers worldwide.

First Advantage shares were trading at $23.18, up $0.71 or 3.16% from the previous close of $22.47, as of 12:46:10 p.m. EST on November 5, 2026. The stock opened at $23.51 and recorded a high of $24.69 and a low of $22.10 during the session.

Also Read: How to invest in US stocks

BHAV Acquisition Shares Hold At $10.10 As $400 Million Nemi Merger Targets Q1 2027

BHAV Acquisition Corp. (NASDAQ: BHAV) has entered into a definitive business combination agreement with Nemi Corp., a manufacturing and artificial intelligence (AI) company, in a transaction that values Nemi at a $400 million pre-money equity valuation. The merger is expected to close in the first quarter of 2027, subject to shareholder approvals, regulatory clearances and other customary closing conditions.

Under the all-stock agreement, Nemi will become a publicly traded company, with its Class A common stock expected to list on the Nasdaq under the ticker symbol NEMI. The transaction does not include an earnout provision. Nemi is also targeting a $50 million private investment in public equity (PIPE) at $10 per share. Assuming the PIPE is fully raised and no redemptions by BHAV’s public shareholders, the combined company is expected to have approximately $142.5 million in cash at closing, after expenses.

Nemi operates more than 300,000 square feet of manufacturing space in India, producing precision metal components, tooling, electronics, batteries, motors and plastics for aerospace, defence and automotive customers. It serves more than 50 enterprise customers and holds AS9100D and ISO 9001 certifications.

The company is also developing a Large Manufacturing Model, an AI platform designed to automate product design, engineering and manufacturing processes. In fiscal 2025, its Manufacturing-as-a-Service (MaaS) business recorded 38% year-over-year revenue growth and a gross margin of 32.5%. Its consolidated gross margin improved to 17.7% from 3.1% in 2024.

As of October 14, 2026, Nemi had more than $14 million in open purchase orders from 16 customers. It also reported non-binding letters of intent from existing customers representing more than $100 million in indicative revenue through 2028. Management targets an operating annualised revenue run-rate of approximately $120 million 12 months after closing, compared with around $20 million expected at closing.

BHAV Acquisition shares were trading at $10.10, unchanged (0.00%), according to the latest supplied market data.

Palantir Shares Fall 9.88% Despite New Enterprise AI Partnership With AmeriLife

AmeriLife Group, LLC, a US-based insurance and retirement solutions provider, announced an enterprise-wide partnership with Palantir Technologies Inc. (NASDAQ: PLTR) on November 5, 2026, to introduce artificial intelligence (AI)-driven capabilities across its Health and Wealth distribution businesses. The agreement will bring Palantir’s Foundry and Artificial Intelligence Platform (AIP) into AmeriLife’s operations, beginning with Crump Life Insurance Services.

The partnership aims to establish an AI-driven operating model built on a unified data foundation rather than adding AI tools to existing processes. The companies intend to use the technology across multiple business functions to improve workflow efficiency, accelerate operations and provide greater visibility to insurance agents, financial advisors and carrier partners.

The collaboration is already producing operational results at Crump Life Insurance Services following a successful pilot. Palantir-powered capabilities are now in production as part of the next generation of Crump’s ACE platform, which supports case management and back-office operations. Deployment across AmeriLife’s wider enterprise is also underway, with additional AI-driven workflows planned over the coming months.

AmeriLife Chairman and CEO Scott R. Perry said the partnership would help transform the company’s operations, from initial client interactions to policy placement. Palantir’s Chief Revenue and Legal Officer Ryan Taylor said the deployment would bring AI capabilities across AmeriLife’s Health and Wealth businesses in a complex and highly regulated industry.

Palantir shares were trading at $154.74, down $16.96 or 9.88% from the previous close of $171.70, as of 1:35:36 p.m. EST on November 5, 2026. The stock opened at $166.72 and recorded a high of $167.25 and a low of $152.60 during the session.

Uranium Energy Shares Fall 9.67% Despite 1.1 Million-Pound U.S. Supply Agreements

Uranium Energy Corp. (NYSE American: UEC) announced that its subsidiary, UEC US Uranium LLC, has signed long-term uranium sales agreements with two US nuclear utilities to supply a combined 1.1 million pounds of uranium concentrates over six years. The agreements cover deliveries from 2027 through 2032 and 2028 through 2032, respectively.

Under the contracts, the company will deliver 100,000 pounds annually to each utility. Pricing for all deliveries will be based on prevailing spot market rates, without floors, ceilings, discounts or fixed-price arrangements. The agreements maintain Uranium Energy’s unhedged pricing strategy, under which the company reported an average realised uranium price of $93.13 per pound in fiscal year 2026.

Scott Melbye, Executive Vice President of Uranium Energy, said the company was pleased to partner with the two American utilities and provide a reliable and competitive domestic uranium supply.

The company also highlighted potential demand from US nuclear energy and defence initiatives. The National Nuclear Security Administration has identified a requirement for four million pounds of US-origin uranium annually, with deliveries potentially beginning in 2030. Separately, the US Army plans to deploy more than 20 microreactors with similar uranium supply requirements.

Uranium Energy operates uranium production platforms in Wyoming and South Texas, with approximately 12 million pounds per year of licensed production capacity. It also holds uranium resources in Canada’s Athabasca Basin. The latest agreements add to its ongoing engagement with domestic and international utilities for long-term uranium supply arrangements.

Uranium Energy shares were trading at $6.50, down $0.70 or 9.67% from the previous close of $7.19, as of 1:45:52 p.m. EST on November 5, 2026. The stock opened at $7.20 and recorded a high of $7.27 and a low of $6.11 during the session.

Agility Robotics Debuts on Nasdaq as AGLT, Secures $300 Million Digit 5 Orders

Agility Robotics (Nasdaq: AGLT) began trading on the Nasdaq Stock Market on November 5, 2026, becoming the first publicly listed pure-play humanoid robotics company in the United States. Its common stock trades under the ticker symbol AGLT, while its warrants trade as AGLTW. The public listing follows the completion of its previously announced business combination with Churchill Capital Corp XI.

The business combination and related financings generated approximately $465 million in gross capital before transaction expenses. The funding includes proceeds from a private investment in public equity (PIPE) led by Foxconn and $100 million in equity funding received before the transaction closed. Agility intends to use the proceeds to fulfil customer orders, expand commercial deployments, increase robot production and advance its robotics and physical AI platforms.

The company enters the public market with nearly three years of real-world deployment experience and more than 65,000 operating hours. It has secured over $300 million in committed multi-year orders for its next-generation Digit 5 humanoid robots, subject to contractual milestones, product features and specifications.

Agility’s flagship Digit robot is already deployed with major enterprises, including GXO, Schaeffler and Toyota Motor Manufacturing Canada. Its expanded agreement with GXO includes deployments at two additional US logistics facilities in early 2027. Digit has also moved more than 100,000 totes at GXO’s Georgia facility.

The company is developing Digit 5 to perform industrial tasks involving repetitive lifting and material handling. Early customer access is expected in the first half of 2027, with general availability targeted for the end of that year.

Agility operates RoboFab, a 70,000-square-foot manufacturing facility in Salem, Oregon, with an annual production capacity of up to 10,000 robots. It also has facilities in Fremont, California, and Pittsburgh, Pennsylvania, supporting hardware development, artificial intelligence, software and customer operations.

Share price reaction: Agility Robotics shares (AGLT) were reported down 4.26% on November 5, 2026. The supplied reference material does not include the latest trading price, opening price or session high and low.

Also Read: US Stock Market Timings 

Rezera Targets $216.7 Million Nasdaq IPO as GSK Plans Up to $25 Million Investment

Drug developer Rezera launched its US initial public offering (IPO) roadshow on November 5, 2026, seeking to raise up to $216.7 million as biotechnology companies continue pursuing stock market listings. The Boston-based company plans to offer 16.7 million shares at an indicative price range of $11 to $13 per share. It will list on the Nasdaq under the ticker symbol RZRA.

At the upper end of the proposed price range, Rezera would have an estimated valuation of approximately $270 million. Pharmaceutical company GSK is expected to purchase up to $25 million worth of shares in the offering. This investment is linked to an earlier agreement between the companies that established a right of first negotiation and a clinical advisory board arrangement.

Under the agreement, GSK receives a right of first negotiation concerning certain late-stage clinical trial data, a potential sale of Rezera’s lead drug candidate, ruvonoflast, and a potential change of control of the company.

Rezera is developing a portfolio of medicines targeting inflammatory drivers of cardiovascular and neurological diseases. Its lead experimental candidate, ruvonoflast, has completed mid-stage clinical trials and is progressing towards late-stage development.

The IPO comes as biotechnology companies continue accessing public markets despite relatively subdued activity across the broader US listing market. Aspen Neuroscience and Bambusa Therapeutics completed their public listings the previous week, while Swiss drug developer Windward Bio filed for a US IPO in October.

Since its establishment in 2016, Rezera has raised approximately $200 million in equity financing from investors including Blue Owl Capital, Epidarex Capital, Novo Holdings and Sofinnova Partners. However, the company reported cash and cash equivalents of $3.9 million as of June 30, 2026, which it expects to support operations until January 2027.

Jefferies, TD Cowen and Cantor are acting as joint bookrunners, while Wedbush PacGrow is serving as lead manager. The proposed IPO will provide Rezera with an opportunity to raise additional capital to support its drug development activities.

SS&C Raises $1.05 Billion Through 2.75% Convertible Notes to Refinance Debt

SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) announced the pricing of $1.05 billion in aggregate principal amount of 2.75% Convertible Senior Notes due 2031 through a private placement to qualified institutional buyers. The offering was increased from the previously announced $1 billion, with an option allowing initial purchasers to acquire an additional $150 million in notes during a 13-day period beginning on the issuance date.

The notes will carry an annual interest rate of 2.75%, payable semiannually on June 1 and December 1, beginning June 1, 2027. They will mature on December 1, 2031, and represent general senior unsecured obligations of SS&C, guaranteed by SS&C Technologies, Inc. and certain wholly owned domestic subsidiaries.

SS&C expects net proceeds of approximately $1.029 billion after deducting the initial purchasers’ discount. The company plans to allocate approximately $99 million towards capped call transactions and repurchase around $100 million of its common stock. The remaining proceeds, together with other borrowings, will be used to redeem all $2 billion of its outstanding 5.500% Senior Notes due 2027.

The convertible notes carry an initial conversion rate of 10.0540 shares per $1,000 principal amount, equivalent to approximately $99.46 per share. This represents a 25% premium over the company’s Tuesday closing price of $79.57. The capped call transactions have an initial cap price of approximately $139.25 per share.

SS&C shares were trading at $78.54, down $1.03 or 1.30% from the previous close of $79.57, as of 2:16:17 p.m. EST on November 5, 2026. The stock opened at $80.00 and recorded a high of $81.59 and a low of $78.29 during the session.

3D Systems Shares Plunge 35.48% After Launching $42.5 Million ATM Stock Offering

3D Systems Corporation (NYSE: DDD) entered into an agreement with Cantor Fitzgerald & Co. to sell up to $42.5 million in common stock through an at-the-market (ATM) offering, according to a November 5, 2026, filing with the US Securities and Exchange Commission. Under the agreement, Cantor Fitzgerald will act as the sales agent or principal and receive commissions of up to 3% of gross sales.

The ATM programme allows 3D Systems to raise capital gradually by selling shares at prevailing market prices rather than completing a single large offering. The company is not obligated to sell any shares and can suspend the programme at any time. Either party can terminate the agreement with 10 business days’ written notice.

The financing arrangement follows the company’s mixed third-quarter 2026 results. Revenue increased 8.8% year over year to $99.3 million, while adjusted EBITDA turned positive at $3.1 million. However, 3D Systems reported a net loss of $33.5 million during the quarter.

As of September 30, 2026, the company held $120.5 million in cash and investments. It also reported operating cash outflows of $17.5 million during the first nine months of the year.

The latest programme follows a roughly $50 million equity offering completed in June, through which the company issued approximately 16.4 million additional shares. The new ATM arrangement provides another potential source of equity financing.

3D Systems shares were trading at $1.705, down $0.935 or 35.48% from the previous close of $2.64, as of 2:20:42 p.m. EST on November 5, 2026. The stock opened at $2.06 and recorded a high of $2.042 and a low of $1.70 during the session.

Also Read: What Are Fractional Shares? 

Precision BioSciences Shares Rise 22.76% After Pricing $125 Million Stock Offering

Precision BioSciences, Inc. (NASDAQ: DTIL), a clinical-stage gene-editing company, announced the pricing of an underwritten offering expected to generate approximately $125 million in gross proceeds before underwriting discounts, commissions and offering expenses.

The offering comprises 10,235,077 shares of common stock priced at $7.75 per share and pre-funded warrants to purchase up to 5,893,964 additional shares at $7.749995 per warrant. The pre-funded warrants carry an exercise price of $0.000005 per share. Both the common stock and pre-funded warrants are being sold directly by Precision BioSciences.

The offering attracted participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments and Driehaus Capital Management.

Precision BioSciences intends to use the net proceeds to support continued research and development of its PBGENE-HBV and PBGENE-DMD programmes, alongside working capital and general corporate purposes. The offering is expected to close on or around November 6, 2026, subject to customary closing conditions.

The company’s proprietary ARCUS gene-editing platform is being used to develop in vivo gene-editing therapies targeting diseases with significant unmet medical needs. TD Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.

Precision BioSciences shares were trading at $9.96, up $1.84 or 22.76% from the previous close of $8.12, as of 2:41:16 p.m. EST on November 6, 2026. The stock opened at $8.49 and recorded a high of $11.29 and a low of $8.40 during the session.

Today’s trading session saw mixed reactions to corporate earnings, revised guidance, acquisitions, financing activities and strategic partnerships. Advanced Drainage Systems and Akebia Therapeutics recorded sharp declines following disappointing results and weaker revenue, while Oscar Health and Aspen Aerogels reported earnings and revenue growth. First Advantage gained after its $125 million acquisition, whereas Palantir and Uranium Energy fell despite new business developments. SS&C and 3D Systems announced financing initiatives, while Agility Robotics began Nasdaq trading. Precision BioSciences also advanced following its $125 million offering.